An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.
Sanchorawala
Vaishali
V
Section of Hematology/Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA. Vaishali.Sanchorawala@bmc.org
Seldin
David C
DC
D000465:Algorithms; D000686:Amyloidosis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D033581:Stem Cell Transplantation / Q000379:methods*
D019653:Myeloablative Agonists; D008558:Melphalan